

**International Journal of Biology, Pharmacy  
and Allied Sciences (IJBPAS)**  
*'A Bridge Between Laboratory and Reader'*

[www.ijbpas.com](http://www.ijbpas.com)

---

---

**RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE  
SIMULTANEOUS ESTIMATION OF METOPROLOL SUCCINATE  
AND RAMIPRIL IN BULK AND MARKETED FORMULATION**

**A. SAI TEJASWI\*, Ch. JASWANTH KUMAR, M. SIVA PRASAD, P. PRACHET  
AND N. RAMA RAO**

Department of Pharmaceutical Analysis, Chalapathi Institute of Pharmaceutical Sciences,  
Chalapathi Nagar, Lam, Guntur-522034

\*Corresponding Author: A. Sai Tejaswi: E Mail Id: [avalasaitejaswi@gmail.com](mailto:avalasaitejaswi@gmail.com)

Received 13<sup>th</sup> March 2021; Revised 12<sup>th</sup> April 2021; Accepted 20<sup>th</sup> May 2021; Available online 1<sup>st</sup> Feb. 2022

<https://doi.org/10.31032/IJBPAS/2022/11.2.5856>


**ABSTRACT**

The main aim of this research work is to estimate and validate the Metoprolol Succinate and Ramipril in bulk and marketed formulation. Method development was carried out by autosampler HPLC Shimadzu 2030C 3D plus was used with stationary phase YMC column (150 × 4.6 mm, 3 μm) with ambient temperature. The mobile phase-A consisting of 0.1 ml orthophosphoric acid in 100 ml water and mobile phase-B consisting of Acetonitrile in gradient mode was pumped into the column at a flow rate of 1.0 mL/min. The injection volume was 20 μL with photo diode array detector at 225 nm. Validation was done according to ICH Q2 (R1) guidelines. Linearity for Metoprolol Succinate was 50-250μg/mL, and Ramipril was 10-50μg/mL with the correlation coefficient [R<sup>2</sup>] 0.9998 and 0.9994. The percentage recoveries were found to be within limits of acceptance criteria between the ranges of 98-102%. Precision results were found to be within limits and method was found to be robust with %RSD limit of NMT 2.0. The method was validated statistically and was applied successfully for estimation of Metoprolol Succinate and Ramipril. All the parameters like theoretical plates, resolution, tailing factor and % RSD was within the acceptance limits. Hence the proposed method can be successfully applied to routine analysis.

**Keywords: Metoprolol Succinate, Ramipril, RP-HPLC, Validation**

## INTRODUCTION


Metoprolol Succinate (**Figure 1**), it is {butanedioic acid; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino) propan-2-ol. It has a molecular formula of  $C_{35}H_{56}N_2O_{10}$  and molecular weight of 652.8 g/mol. Metoprolol succinate is an antihypertensive agent ( $\beta_1$ -Adrenergic blocker). Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety. Metoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at  $\beta_1$ -adrenergic receptors in the heart.  $\beta_1$ -receptor blockade results in a decrease in heart rate, cardiac output, and blood pressure [1].



**Figure 1: Structure of Metoprolol Succinate**

Ramipril (**Figure 2**), it is 4-[2-(1-ethoxycarbonyl-3-phenyl-propyl)aminopropanoyl]-4-azabicyclooctane-3-carboxylic acid is a long-acting angiotensin converting enzyme (ACE) inhibitor and it is a prodrug, which is hydrolysed after absorption to form the active metabolite ramiprilate which has a long elimination half-life, permitting once daily administration. Ramipril may be effective

in indications such as displayed beneficial effects in patients with moderate to severe congestive heart failure [2].



**Figure 2: Structure of Ramipril**

## MATERIALS AND METHODS

The pharmaceutical grade samples of Metoprolol Succinate and Ramipril were procured from Sigma Aldrich. Orthophosphoric acid, Acetonitrile and HPLC grade water of analytical grade were obtained from national scientific products. The tablet formulation containing 25mg of Metoprolol Succinate and 2.5mg of Ramipril were procured from local market.

### Chromatographic conditions:

A HPLC equipped with PDA detector was used. The chromatographic analysis was performed on column of YMC (150 x 4.6mm) 3 $\mu$ m. Mobile phase-A consisting of Orthophosphoric acid and mobile phase-B is Acetonitrile was used in gradient mode, with detection of 225nm. An injection volume of 20 $\mu$ L was used, keeping flow rate of 1mL/min.

### Preparation of Orthophosphoric acid:

Accurately 0.1mL of orthophosphoric acid was pipette out in 100mL volumetric flask

and the volume was made up to 100mL with HPLC water and it was filtered through 0.45 $\mu$  membrane filter and sonicated for 10minutes.

#### Preparation of standard stock solution:

About 10mg of Metoprolol Succinate and Ramipril were weighed and transferred into a separate 10mL volumetric flasks and dissolved in acetonitrile and water (50:50v/v) and made up to the volume to obtain 1000 $\mu$ g/mL.

#### Preparation of sample solution:

About 10mg of tablet powder was accurately weighed which is calculated

based on average weight of 20 tablets and dissolved in acetonitrile and water (50:50v/v) in 10mL volumetric flask. From the above stock solution 0.1mL was pipette out in 10mL volumetric flask and the solution was made up to the volume with acetonitrile and water (50:50v/v).

#### Method Development:

#### Optimized chromatographic conditions:

**Column:** YMC C<sub>8</sub> (150 $\times$ 4.6mm) 3 $\mu$ m

**Wavelength:** 225nm

**Flow rate:** 1.0 mL/min

**Injection volume:** 20 $\mu$ L

**Run time:** 11.01min

Table 1: Gradient Mode of Mobile Phase

Time (min)	MP-A (0.1% OPA)	MP-B (ACN)
0.01	75	25
3.00	75	25
5.00	50	50
7.10	25	75
9.00	75	25
11.00	75	25
11.01	Stop	




Figure 3: Standard Chromatogram




Figure 4: Sample Chromatogram

**Method Validation:**

The proposed method was validated according to the ICH guidelines which include system suitability, specificity, linearity, accuracy, precision, Limit of Detection (LOD), Limit of Quantification (LOQ) and robustness. Under the validation study, the following parameters were studied.

**RESULTS****System Suitability:**

HPLC system was optimized as per the chromatographic conditions. 20  $\mu$ L of standard solutions of drugs were injected in six times into the chromatographic system. To ascertain the system suitability for the proposed method, the parameters such as retention time, number of theoretical plates, resolution, tailing factor and % RSD were calculated and compared with standard specification of system (Table 2).

**Specificity:**

The specificity of method was determined by comparing the chromatograms of blank, standard and sample.

**Linearity:**

Linearity of the method was analyzed by preparing calibration curves using different concentrations of the standard solutions. Linearity was established from 50-

250  $\mu$ g/mL for Metoprolol Succinate and 10-50  $\mu$ g/mL for Ramipril (Figure 5-6, Table 2).

**Accuracy:**

The accuracy was performed by preparing known amount of samples at 50%, 100% and 150% levels. They were injected in a triplicate at each level (Table 4).

**Precision:**

System and Method precision was carried out for Metoprolol Succinate and Ramipril by giving six injections (Table 5).

**Limit of Detection (LOD) and Limit of Quantification (LOQ):**

The LOD of Metoprolol Succinate and Ramipril was found to be 5  $\mu$ g/mL and 1  $\mu$ g/mL and LOQ for Metoprolol Succinate and Ramipril was found to be 15  $\mu$ g/mL and 3  $\mu$ g/mL which indicates the sensitivity of the method.

**Robustness:**

The standard solutions of Metoprolol Succinate and Ramipril were injected by changing the chromatographic conditions like flow rate of the mobile phase and wavelength (Table 6).

**Assay:**

The % Purity of Metoprolol Succinate and Ramipril was found to be 100.07% and 100.70% respectively.

Table 2: Data of System Suitability

Metoprolol Succinate			Ramipril	
Injection No	Retention Time (min)	Peak Area	Retention Time (min)	Peak Area
1	2.630	653811	7.070	2823553
2	2.648	658428	7.083	2821908
3	2.75	651354	7.009	2862771
4	2.585	659494	7.024	2847090
5	2.592	662339	7.021	2848972
6	2.569	650238	7.023	2853414
Mean 655944			2842951	
Standard Deviation 4854.72			16581.8	
%RSD 0.74			0.58	
Tailing factor		1.202	1.143	
Theoretical plates		5213	4512	




Figure 5: Calibration Curve of Metoprolol Succinate




Figure 6: Calibration Curve of Ramipril

Table 3: Data of Linearity

Metoprolol Succinate		Ramipril	
Concentration (µg/mL)	Peak area	Concentration (µg/mL)	Peak area
50	195088	10	1019757
100	397871	20	1841386
150	600913	30	2816518
200	783227	40	3607326
250	984944	50	4505067
$R^2 = 0.9998$		$R^2 = 0.9994$	

Table 4: Data of Accuracy

Drug	% Level	Standard peak area	Sample peak area	% Recovery	% Average Recovery	% Overall Mean recovery
Metoprolol Succinate	50%	28422951	1442951	100.46	100.43	100.56%
		2842951	1425951	100.59		
		2842951	1412951	100.24		
	100%	2842951	2869415	100.55	100.19	
		2842591	2819168	99.81		
		2842591	2870991	100.22		
	150%	2842591	4308080	101.30	101.04	
		2842591	4298591	100.98		
		2842591	4306891	100.91		
Ramipril	50%	655944	330128	101.31	100.66	100.78%
		655944	329845	100.33		
		655944	328954	100.34		
	100%	655944	658745	101.05	100.67	
		655944	658745	99.90		
		655944	656897	101.06		
	150%	655944	996589	101.03	101.02	
		655944	992584	100.90		
		655944	991458	101.14		

Table 5: Data of System Precision and Method Precision

Injection No	System Precision		Method Precision	
	Metoprolol Succinate	Ramipril	Metoprolol Succinate	Ramipril
1	651411	2823553	650241	2823953
2	658418	2821908	657428	2824908
3	659354	2862771	651054	2862571
4	657944	2847090	653029	2847090
5	650149	2848972	656839	2848572
6	658958	2843514	659958	2853314
Mean	656039	2841301	654758.2	2843401
SD	4120.896	15806.93	3888.748	15660.91
%RSD	0.63	0.56	0.59	0.55

Table 6: Data of Robustness

S. No	Parameters	Metoprolol Succinate			Ramipril		
		R <sub>t</sub> (min)	Peak area	%RSD	R <sub>t</sub> (min)	Peak area	%RSD
1.	Change in flow rate- 0.8mL/min	3.08	601287	0.39	7.749	2826513	0.75
		3.10	604592	0.36	7.752	2856590	0.78
2.	Change in flow rate- 1.2mL/min	2.105	606987	0.35	6.361	2828427	0.70
		2.108	603690	0.35	6.364	2856548	0.72
3.	Change in wavelength 220nm	2.575	5892856	0.27	7.009	2216548	0.48
		2.579	5870134	0.26	7.011	2231680	0.51
4.	Change in wavelength 230nm	2.585	6255530	0.25	7.024	2953142	0.56
		2.588	6279401	0.25	7.028	2976830	0.58

## CONCLUSION

A simple, sensitivity, precise and specific reverse phase high performance liquid chromatography (RP-HPLC) method was developed and validated for estimation of Metoprolol Succinate and Ramipril in tablet dosage form. The separation was

performed on YMC (150mm x 4.6mm, 3µm) chromatographic column with the mobile phase-A was Orthophosphoric acid buffer and mobile phase-B was Acetonitrile with the flowrate of 1.0mL/min and detection wavelength at 225nm. The developed method was validated according

to ICH guidelines. The linearity range was 50-250 µg/mL for Metoprolol Succinate and 10-50 µg/mL for Ramipril with a correlation coefficient of 0.9998 and 0.9994 respectively. The percentage recoveries were found to be within limits of acceptance criteria between the ranges of 98-102%. Precision results were found to be within limits and method was found to be robust with %RSD limit of NMT 2.0. The method was validated statistically and was applied successfully for estimation of Metoprolol Succinate and Ramipril.

#### Acknowledgement:

I am very grateful to Chalapathi Institute of Pharmaceutical Sciences, Lam, Guntur, for giving support, guidance and facilities.

#### REFERENCES

- [1] Yunoos, Md., Gowri Sankar, D., (2015). "A new validated stability indicating LC method for simultaneous determination of metoprolol succinate and ramipril in pharmaceutical marketed formulation", Scholar Res Lib. 7(4): Pp. 82-92.
- [2] Kamini, S., Janhavi Rao, R., Raja Rajeswari, K., and Kev, N., (2019). "Validated HPTLC method for simultaneous estimation of metoprolol succinate and ramipril in bulk drug and marketed formulation", Clin Med Rep. 2: Pp. 1-4.
- [3] Vipul, Patel., DR. Saurabh, Pandya., (2017). "Analytical method development and validation for simultaneous estimation of metoprolol succinate and ramipril in tablet dosage form by RP-HPLC", Int. J. Pharm. Res. & Bio-sci. 6(3): Pp. 41-50.
- [4] Krishna Kishor, P., Padmavathi, P., Prabhu & Chethan, SH., (2017). "Development and validation of new analytical methods for simultaneous estimation of ramipril and metoprolol succinate by HPLC method in combined tablet dosage form", Int. J. Pharm. & Chem. Res. 3(4): Pp. 746-755.
- [5] Sonali Chaudhari, M., Karan, M., Prajapati, Shailesh, V., Luhar, (2018). "RP-HPLC method development and validation for simultaneous estimation of Atorvastatin, Aspirin, Ramipril and Metoprolol succinate in tablet dosage form", An Int. J. Pharm. Sci. 9(2): Pp. 205-217.
- [6] Mehul Patel, M., & Disha Patel, D., (2012). "Simultaneous estimation of Metoprolol succinate and Olmesartan Medoxomil in pharmaceutical dosage form by RP-HPLC", J. Chromat. Separation Techniq. 3(8):
- [7] Raja Kumar, S., et al., (2010). "Simultaneous Quantitative Determination of Metoprolol, Atorva-statin and Ramipril in Capsules by a Validated Stability-Indicating RP-UPLC Method" Scientia Pharmaceutica. 78: Pp. 821-834.
- [8] Prajakta, S., Shirkhedkar, A., Sanjay, J., Surana, & Amod, S., (2011). "Normal and Reverse -Phase HPTLC Methods

- for Simultaneous Estimation of Telmisartan and Metoprolol Succinate in Pharmaceutical Formulation”, Int. Scholarly Res. Network.
- [9] Moreshwar Kulkarni, N., Rajeshwar, V., & Dinesh, M., (2009). “Development and Validation of Spectrophotometric Method for Determination of Metoprolol Succinate”, Int. J. of ChemTech Res. 1(4): Pp. 1273-1277.
- [10] Venkateswarlu, P., Naresh Kumar, B., Sessaiah, K., V.V. Prasad, V., (2012) “Selective and sensitive method for the determination of metoprolol in human plasma using liquid chromatography couples with tandem mass spectroscopy”, Acta Pharm. 60: Pp. 177-184.
- [11] Alekhya, B., Sindhusa, M., Soraj Raul, K., Gopal Pahy, K., (2020). “A new validated third order derivative spectroscopic method for simultaneous estimation of metoprolol succinate and ramipril in tablet dosage form”, Int. J. Pharmacy & Pharm. Sci. 12(5): Pp. 55-58.
- [12] Hari Hara Kumar, S., Sai Kiran, S., Harshini, S., Anand, K., Roja Kumari, V., Dr. Vasudha, B., (2016). “Method development and validation for the simultaneous estimation of Ramipril and Telmisartan in bulk and pharmaceutical dosage form by using RP-HPLC”, Int. J. Innovative Pharm. Sci. & Res. 4(4): Pp. 314-320.
- [13] Sujana, G., Aruna, G., Sivagangaram, G., (2014). “Analytical method development and validation of Ramipril HCL and Metoprolol Tartarate in pure and in combinations by UV Spectrophotometry and RP-HPLC”, Int. J. Pharm. Develop.& Tech. 4(4): Pp. 214-224.
- [14] Manju latha, Y.B., Gowri Sankar, D., (2013). “Stability Indicating RP-HPLC Method for Determination of Ramipril in pure and pharmaceutical formulation”, Asian J. Pharm. & Clini. Res. 6(4): Pp. 158-161.
- [15] Prasad Rao, M., Srikanth, M., Umamaheswari, K., (2017). “Simultaneous estimation of Ramipril and Olmesartan Medoximil by RP-HPLC method”, Int. J. Pharm. Chem. & Analysis, 4(4):Pp. 106-111.